Viatris

Regulatory Burdens Will Squeeze Margins Though Pipeline Will Offer Little

AnalystLowTarget

Not Invested

Community Contributor

Published

22 Aug 25

AnalystLowTarget's Fair Value

US$8.00

21.8% overvalued

04 Sep

US$9.74

-14.4%

-4.4%

-14.4%

-4.4%

You can edit this narrative until Aug 22 10:21 PM. Then, changes will post as Updates.

Author's Valuation

US$821.8% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$8

21.8% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

1.15%

Pharma revenue growth rate

0.67%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.33%

Calculation

US$94.22m

Earnings '28

113.40x

PE Ratio '28

US$10.68b

Market Cap '28

US$10.68b

Market Cap '28

1.09b

No. shares '28

US$9.83

Share Price '28

US$9.83 Share Price '28

Discounted to 2025 @ 7.14% p.a.

US$8.00

Fair Value '25